Basit öğe kaydını göster

dc.contributor.authorAsena, L.
dc.contributor.authorOzdemir, E.Singar
dc.contributor.authorBurcu, A.
dc.contributor.authorErcan, E.
dc.contributor.authorColak, M.
dc.contributor.authorAltınors, D.D.
dc.date.accessioned2019-06-13T12:08:34Z
dc.date.available2019-06-13T12:08:34Z
dc.date.issued2017
dc.identifier.issn0950-222X
dc.identifier.urihttps://www.nature.com/articles/eye20174.pdf
dc.identifier.urihttp://hdl.handle.net/11727/3500
dc.description.abstractPurpose To compare the clinical outcome with different treatment regimens in Acute Adenoviral Keratoconjunctivitis (AAK). Methods The records of 110 patients diagnosed as AAK in two tertiary eye care centers were evaluated retrospectively. The treatment regimen, follow-up duration, time until improvement of the symptoms, visual acuity, clinical findings, Schirmer's test and the Ocular Surface Disease Index (OSDI) score at the first day, first week and third week were recorded. The Kruskal-Wallis Test and Chi-square test were used for comparison of quantitative and categorical variables, respectively. Results Forty six patients were receiving topical corticosteroids (Group 1), 32 topical 2% Cyclosporin A (CsA) (Group 2) and 32 only artificial tears (Group 3). Mean time until resolution of the symptoms was lowest in Group 1 (9.5 +/- 4.9 days) and highest in Group 3 (13.3 +/- 4.2 days)(p: 0.001). OSDI scores at the first and third weeks were highest in Group 3 (52.4 +/- 16.4 and 32.3 +/- 13.0) and lowest in Group 1 (41.0 +/- 21.3 and 23.9 +/- 13.2)(p: 0.01 and p: 0.009). At day 21, percentage of the patients with subepthelial infiltrates was the highest in Group 3 (63.4%) and lowest in Group 1 (42.5%). Conclusions The symptoms were less severe and had a shorter duration with topical corticosteroids and CsA when compared with palliative therapy. Topical 2% CsA may inhibit development of corneal subepithelial infiltrates when used in the acute phase of infection, similar to corticosteroids.en_US
dc.language.isoengen_US
dc.relation.isversionof10.1038/eye.2017.4en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectTOPICAL CYCLOSPORINE-Aen_US
dc.subjectEPIDEMIC KERATOCONJUNCTIVITISen_US
dc.subject1-PERCENT CYCLOSPORINEen_US
dc.subjectPOVIDONE-IODINEen_US
dc.subjectEYE DROPSen_US
dc.subjectRABBITen_US
dc.subjectDEXAMETHASONEen_US
dc.subjectINFECTIONen_US
dc.subjectKERATITISen_US
dc.subjectCIDOFOVIRen_US
dc.titleComparison of clinical outcome with different treatment regimens in acute adenoviral keratoconjunctivitisen_US
dc.typearticleen_US
dc.relation.journalEYEen_US
dc.identifier.volume31en_US
dc.identifier.issue5en_US
dc.identifier.startpage781en_US
dc.identifier.endpage787en_US
dc.identifier.wos000401036900019en_US
dc.identifier.scopus2-s2.0-85044551564en_US
dc.contributor.pubmedID28157224en_US
dc.contributor.orcID0000-0002-6848-203Xen_US
dc.contributor.orcID0000-0001-5223-0279en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.contributor.researcherIDE-5914-2016en_US
dc.contributor.researcherIDAAK-8077-2021en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster